A
Agilent Technologies Inc
$
151.250
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
151.760
Open
144.470
VWAP
150.20
Vol
2.47M
Mkt Cap
42.88B
Low
144.470
Amount
370.86M
EV/EBITDA(TTM)
24.74
Total Shares
291.76M
EV
44.75B
EV/OCF(TTM)
29.94
P/S(TTM)
6.36
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
1.76B
+5.35%
1.409
+7.53%
1.78B
+6.13%
1.426
+8.82%
1.83B
+7.73%
1.583
+8.41%
Estimates Revision
The market is revising Upward the revenue expectations for Agilent Technologies, Inc. (A) for FY2025, with the revenue forecasts being adjusted by 1.97% over the past three months. During the same period, the stock price has changed by 24.35%.
Revenue Estimates for FY2025
Revise Upward
+1.97%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.23%
In Past 3 Month
Stock Price
Go Up
+24.35%
In Past 3 Month
14 Analyst Rating
-0.88% Downside
Wall Street analysts forecast A stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 149.92 USD with a low forecast of 125.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
6 Hold
0 Sell
Moderate Buy
-0.88% Downside
Current: 151.250
Low
125.00
Averages
149.92
High
170.00
-0.88% Downside
Current: 151.250
Low
125.00
Averages
149.92
High
170.00
TD Cowen
Buy
maintain
$150 -> $162
2025-10-14
Reason
TD Cowen
Price Target
$150 -> $162
2025-10-14
maintain
Buy
Reason
TD Cowen raised the firm's price target on Agilent to $162 from $150 and keeps a Buy rating on the shares. The firm said they expect 2026 organic guidance of around 5% which is roughly in line with consensus, with EBIT expansion likely a bit below consensus at +70bp year-over-year, hence our F26 EPS is below consensus but with a good F4Q coming, Biopharma turning, idiosyncratic drivers and likely upside to F26 forecasts they reiterate their Buy rating.
BofA
Neutral
maintain
$128 -> $130
2025-09-22
Reason
BofA
Price Target
$128 -> $130
2025-09-22
maintain
Neutral
Reason
BofA raised the firm's price target on Agilent to $130 from $128 and keeps a Neutral rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to "normal."
Wells Fargo
Brandon Couillard
Overweight
maintain
$135 -> $140
2025-08-28
Reason
Wells Fargo
Brandon Couillard
Price Target
$135 -> $140
2025-08-28
maintain
Overweight
Reason
Wells Fargo analyst Brandon Couillard raised the firm's price target on Agilent to $140 from $135 and keeps an Overweight rating on the shares. The firm notes the company posted impressive core growth upside, but in line EPS. While higher tariff costs limited more EPS upside, Wells is encouraged by Agilent's accelerating core growth momentum, which is trending ahead of most Tools peers.
Barclays
Luke Sergott
Equal Weight
maintain
$115 -> $125
2025-06-24
Reason
Barclays
Luke Sergott
Price Target
$115 -> $125
2025-06-24
maintain
Equal Weight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Agilent to $125 from $115 and keeps an Equal Weight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
JPMorgan
Overweight
to
Overweight
downgrade
$160 -> $155
2025-05-29
Reason
JPMorgan
Price Target
$160 -> $155
2025-05-29
downgrade
Overweight
to
Overweight
Reason
JPMorgan lowered the firm's price target on Agilent to $155 from $160 and keeps an Overweight rating on the shares. The company reported a fiscal Q2 beat and reiterated 2025 core revenue growth and earnings guidance, the analyst tells investors in a research note. The firm updated Agilent's forward estimates.
UBS
Dan Leonard
Neutral
downgrade
$150 -> $130
2025-05-29
Reason
UBS
Dan Leonard
Price Target
$150 -> $130
2025-05-29
downgrade
Neutral
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Agilent Technologies Inc (A.N) is 25.49, compared to its 5-year average forward P/E of 25.66. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
25.66
Current PE
25.49
Overvalued PE
29.91
Undervalued PE
21.41
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
20.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.94
Undervalued EV/EBITDA
17.69
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
5.84
Current PS
0.00
Overvalued PS
6.60
Undervalued PS
5.08
Financials
Annual
Quarterly
FY2025Q3
YoY :
+10.14%
1.74B
Total Revenue
FY2025Q3
YoY :
-5.75%
377.00M
Operating Profit
FY2025Q3
YoY :
+19.15%
336.00M
Net Income after Tax
FY2025Q3
YoY :
+21.65%
1.18
EPS - Diluted
FY2025Q3
YoY :
-28.06%
259.00M
Free Cash Flow
FY2025Q3
YoY :
-6.26%
51.50
Gross Profit Margin - %
FY2025Q3
YoY :
-26.50%
16.03
FCF Margin - %
FY2025Q3
YoY :
+8.17%
19.33
Net Margin - %
FY2025Q3
YoY :
-18.29%
14.21
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 702.37% over the last month.
Sold
0-3
Months
2.3M
USD
3
3-6
Months
404.9K
USD
3
6-9
Months
444.5K
USD
2
0-12
Months
286.6K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
99.7K
Volume
2
0-12
Months
144.8K
Volume
7
Bought
0-3
0
0.0
Volume
Months
3-6
3
91.8K
Volume
Months
6-9
5
1.5M
Volume
Months
0-12
9
2.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
16.0K
USD
2
6-9
Months
145.5K
USD
9
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
16.0K
USD
Months
6-9
5
89.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 702.37% over the last month.
Sold
0-3
Months
2.3M
USD
3
3-6
Months
404.9K
USD
3
6-9
Months
444.5K
USD
2
0-12
Months
286.6K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
A News & Events
Events Timeline
2025-10-27 (ET)
2025-10-27
16:16:32
Agilent appoints new Chief Financial Officer
2025-09-30 (ET)
2025-09-30
08:17:44
Agilent unveils Insight Series alarm resolution systems for enhancing airport security
2025-09-02 (ET)
2025-09-02
08:09:12
Agilent pharmDx awarded EU Class C certification for companion diagnostics
Sign Up For More Events
Sign Up For More Events
News
4.5
01:16 AMBarron'sDisney Faces Stock Challenges: A Potential Solution Lies in Expanding Cruise Ship Ventures.
8.0
11-20NASDAQ.COMDaily Dividend Update: NVDA, A, WSBC, AVB, HAL, PEP
8.0
11-19NewsfilterAgilent Declares Cash Dividend of 25.5 Cents per Share
Sign Up For More News
People Also Watch
ODFL
Old Dominion Freight Line Inc
134.280
USD
+6.33%
NWG
NatWest Group PLC
15.230
USD
+2.49%
AMX
America Movil SAB de CV
22.880
USD
+0.18%
HLN
Haleon PLC
9.870
USD
+2.81%
CBRE
CBRE Group Inc
156.790
USD
+3.44%
LHX
L3Harris Technologies Inc
277.780
USD
-2.27%
GRMN
Garmin Ltd
192.230
USD
+2.74%
EW
Edwards Lifesciences Corp
85.130
USD
+1.24%
TAK
Takeda Pharmaceutical Co Ltd
14.300
USD
+1.71%
AME
AMETEK Inc
195.020
USD
+2.63%
FAQ
What is Agilent Technologies Inc (A) stock price today?
The current price of A is 151.25 USD — it has increased 4.27 % in the last trading day.
What is Agilent Technologies Inc (A)'s business?
What is the price predicton of A Stock?
What is Agilent Technologies Inc (A)'s revenue for the last quarter?
What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Agilent Technologies Inc (A)'s fundamentals?
How many employees does Agilent Technologies Inc (A). have?